TMCnet News
Surrozen Announces Publication of Antibody Platform Technology in Cell Chemical Biology-- Novel approach to creating Wnt-mimetics establishes proof-of-concept for targeted regenerative antibodies -- SOUTH SAN FRANCISCO, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced a peer-reviewed publication describing its novel platform for generation of potent and selective Wnt-mimetics. The article, “Development of Potent, Selective Surrogate WNT Molecules and Their Application in Defining Frizzled Requirements” was published online today in Cell Chemical Biology. The article describes Surrozen’s Wnt-mimetic platform comprising potent, multivalent antibodies directly activating the Wnt signaling pathway. These multivalent antibodies achieve Fzd receptor specificity and have potential applications as targeted therapeutics for tissue regeneration. The Company’s research identified key requirements for maximal signaling and represents a new approach to utilizing the Wnt signaling pathway to potentially repair a broad range of tissues. “I am proud of all the scientists who contributed to the body of work that supported the publication of these important findings,” said Craig Parker, chief executive officer of Surrozen. “We believe that safely and effectively activating the Wnt pathway will open new avenues for therapeutic discovery in numerous disease areas.” Importat results in the publication include the observation that multivalent binding is required to achieve maximal activation of Wnt signaling and that active receptor complexes can contain different ratios of receptors. Furthermore, the data indicate that recruitment of two different Fzd receptors together with lipoprotein receptor-related protein (LRP) induces efficient signaling. The article will appear in print in a future issue of Cell Chemical Biology. “These results suggest that a tissue-specific Wnt-mimetic can stimulate regeneration in a cell-specific manner and provide a blueprint for constructing a tissue-specific molecule,” said Dr. Yang Li, lead author of the publication and vice president of Biology at Surrozen. “The novel Wnt pathway engineering method described in the article can be tailored to a broad range of tissue types, highlighting the ability of our core technology to impact many different disease areas.” About Wnt Signaling About Surrozen’s Proprietary Antibody Platforms and Harnessing Wnt Signaling About Surrozen Investors/Partners: Reza Afkhami VP, Corporate Development and Strategy Surrozen, Inc. [email protected] Media: Denise Powell Red House Consulting [email protected] |